Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells

References

• Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994; 91(9):3497–3504, Apr 26.
   PubMed Web of Science ®Google Scholar
• Lehnert M. Clinical multidrug resistance in cancer: A multifactorial problem. Eur J Cancer 1996 Jun;32A(6): 912–920, Review.
   PubMed Web of Science ®Google Scholar
• Germann UA. P-glycoprotein a mediator of multidrug resistance in tumour cells. Eur J Cancer 1996 Jun;32A(6): 927–944, Review.
   PubMed Web of Science ®Google Scholar
• Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG, Mehta AB. Expression of the multidrug resistance-associated protein (MRP) in acute leukemia. Leukemia 1994;8(12): 2163–2168, Dec.
   PubMed Web of Science ®Google Scholar
• Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, van der Valk P, Scheper RJ. Major vault protein LRP-related multidrug resistance. Eur J Cancer 1996 Jun;32A(6):979-984, Review.
   PubMed Web of Science ®Google Scholar
• Morrow CS, Cowan KH. Glutathione 5-transferases and drug resistance. Cancer Cells 1990 Jan;2(1):15–22, Review.
   PubMed Web of Science ®Google Scholar
• Nitiss JL, Beck WT Antitopoisomerase drug action and resistance. Eur J Cancer 1996;32A(6):958-966, Jun.
   PubMed Web of Science ®Google Scholar
• Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (1\4DR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89(9):3323–3329, May 1.
   Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukemia Working Parties. Blood 1998;92(7):2322–2333, Oct 1.
   PubMed Web of Science ®Google Scholar
• Hiddeman W, Kern W, Schoch C. Management of acute myeloid leukemia in elderly patients. J Chin Oncol 1999;17: 3569–3576.
   PubMed Web of Science ®Google Scholar
• Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdrl) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78(3):586–592, Aug 1.
   PubMed Web of Science ®Google Scholar
• Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. Natl Cancer Inst 1991;83(10):708–712, May 15.
   Google Scholar
• Del Poeta G, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, Buccisano F, Masi, Tribalto M, Amadori S, Papa G. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996;87(5):1997–2004, Mar 1.
   Web of Science ®Google Scholar
• Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79(2):473–476, Jan 15.
   PubMed Web of Science ®Google Scholar
• Hunault M, Zhou D, Delmer A, Ramond S, Viguie F, Cadiou M, Perrot JY, Levy V, Rio B, Cymbalista F, Zittoun R, Marie JP. Multidrug resistance gene expression in acute myeloid leukemia: Major prognosis significance for in vivo drug resistance to induction treatment. Ann Hematol 1997;74(2): 65–71, Feb.
   Google Scholar
• Nussler V, Pelka-Fleischer R, Zwierzina H, Nerl C, Beckert B, Gieseler F, Diem H, Ledderose G, Gullis E, Sauer H, Wilmanns W. P-glycoprotein expression in patients with acute leukemia-clinical relevance. Leukemia 1996;( 10 Jul Suppl 3): S23—S31.
   PubMedGoogle Scholar
• Wang YH, Motoji T, Motomura S, Shiozaki H, Tsuruo T, Mizoguchi H. Recovery of drug sensitivity by MS-209, a new multidrug resistance-reversing agent, on acute myelogenous leukaemic blasts and K562 cells resistant to adriamycin cell line. Eur J Haematol 1997;58(3):186–194, Mar.
   PubMed Web of Science ®Google Scholar
• Hegewisch-Becker S, Faltz C, Hossfeld DK. Prolongation of medium exchange is associated with a decrease in function but not expression of the P-glycoprotein pump in leukaemic cells. Eur J Haematol 1996;56(1–2): 12-22, Jan—Feb.
   PubMed Web of Science ®Google Scholar
• Basara N, Radosevic-Radojkovic N, Colovic M, Boskovic D, Rolovic Z. In vitro drug sensitivity of leukemic progenitors and P-glycoprotein expression in adult acute myeloid leukemia: Correlation with induction treatment outcome. Eur J Haematol 1995;55(2):83–87, Aug.
   Google Scholar
• Lamy T, Goasguen JE, Mordelet E, Grulois I, Dauriac C, Drenou B, Chaperon J, Fauchet R, he Prise PY. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia 1994;8(11):1879—1883, Nov.
   PubMed Web of Science ®Google Scholar
• Zochbauer S, Gsur A, Brunner R, Kyrle PA, Lechner K, Pirker R. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 1994;8(6): 974–977, Jun.
   PubMed Web of Science ®Google Scholar
• Arceci RJ, Stieglitz K, Bierer BE. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 1992;80(6):1528–1536, Sep 15.
   PubMed Web of Science ®Google Scholar
• Ariyoshi K, Hamada H, Naito M, Heike Y, Seimiya H, Maezawa K, Tsuruo T. Mouse-human chimeric antibody MH171 against the multidrug transporter P glycoprotein. Jpn J Cancer Res 1992;83(5):515–521, May.
   PubMedGoogle Scholar
• Zhou DC, Marie JP, Maisonneuve L, Faussat-Suberville AM, Zittoun R. Effect of differentiating agents on modulation of MDR1 gene expression in multidrug-resistant Hematopoietic HL60/DNR cell line. Exp Hematol 1993;21(6):779–784, Jun.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP dependent transporters. Nat Rev Cancer 2002 Jan;2(1):48–58, Review.
   PubMed Web of Science ®Google Scholar
• Motomura S, Motoji T, Takanashi M, Wang YH, Shiozaki H, Sugawara I, Aikawa E, Tomida A, Tsuruo T, Kanda N, Mizoguchi H. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdrl) antisense oligonucleotides. Blood 1998;91(9):3163–3171, May 1.
   PubMed Web of Science ®Google Scholar
• Rivoltini L, Colombo MP, Supino R, Ballinari D, Tsuruo T, Parmiani G. Modulation of multidrug resistance by verapamil or mdrl anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line. Int J Cancer 1990; 46(4):727–732, Oct 15.
   PubMed Web of Science ®Google Scholar
• Thierry AR, Rahman A, Dritschilo A. Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem Bio-phys Res Commun 1993;190(3):952–956, Feb 15.
   PubMed Web of Science ®Google Scholar
• Vasanthakumar G, Ahmed NK. Modulation of drug resistance in a daunorubicin resistant sub line with oligonucleoside methylphosphonates. Cancer Commun 1989;1(4):225–232.
   PubMedGoogle Scholar
• Hiratake S, Azuma E, Nishiguchi Y, Nagai M, Ido M, Komada Y, Sakurai M. Treatment of multidrug-resistant murine leukemia with antisense mdrl oligodeoxynucleotides. Biomed Pharmacother 1997;51(6-7):276–283.
   Google Scholar
• Slapak CA, Mizunuma N, Kufe DW. Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood 1994;84(9):3113–3121, Nov 1.
   PubMed Web of Science ®Google Scholar
• Zalcberg JR, Hu XF, Wall DM, Mirski S, Cole S, Nadalin G, De Luise M, Parkin JD, Vrazas V, Campbell L, et al. Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line. Int J Cancer 1994;57(4):522–528, May 15.
   PubMed Web of Science ®Google Scholar
• Hu X, Yang H, Pan Q-R, Zheng S. Does P-glycoprotein play a pivotal role in the drug resistance of an MDR variant, K562/Dox? Chemotherapy 1995;41: 296–305.
   PubMed Web of Science ®Google Scholar
• Dassow H, Lassner D, Remke H, Preiss R. Modulation of multidrug resistance in human leukemia cells with mdrl-targeted antisense oligonucleotides using variable treatment schedules. Int J Clin Pharmacol Ther 2000;38(4):209–216, Apr.
   PubMed Web of Science ®Google Scholar
• Li X, Smyth AP, Barrett DJ, Ivy SP, von Hofe E. Sensitization of multidrug-resistant human leukemia cells with MDR1-targeted antisense and inhibition of drug-mediated MDR1 induction. Leukemia 1997;11(7): 950–957, Jul.
   PubMed Web of Science ®Google Scholar
• Ramachandran C, Wellham LL. Effect of MDR1 phosphor-othioate antisense oligodeoxynucleotides in multidrug-resist-ant human tumor cell lines and xenografts. Anticancer Res 2003;23(3B):2681–2690, May—Jun.
   PubMed Web of Science ®Google Scholar
• Thomas M, Jindrich K, Thomas K. Perspects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 2002;54:715–758.
   PubMedGoogle Scholar
• Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci USA 1995;92(16): 7297–7301, Aug 1.
   PubMed Web of Science ®Google Scholar
• Kichler A, Leborgne C, Coeytaux E, Danos O. Polyethyleni-mine-mediated gene delivery: A mechanistic study. J Gene Med 2001;3 (2): 135–144, Mar—Apr.
   PubMed Web of Science ®Google Scholar